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Kaposi sarcoma-associated herpes virus (KSHV), also known as human herpes virus 8 
(HHV8), is aetiologically implicated in Kaposi’s sarcoma (KS).  Although HIV associated KS 
has increased in incidence and is a public health problem in South Africa, serological studies 
of KSHV have not been extensively documented in this population. This cross-sectional study 
investigates the seroprevalence and viral load of KSHV in an adult South African cohort. 
Method 
Cross-sectional data of 140 participants attending an urban research HIV counseling and testing 
(HCT) clinic site in Durban, KwaZulu-Natal, between July and October 2013 was analyzed.    
Detection of antibodies against latent (Orf73) and lytic (K8.1) KSHV antigens was performed 
on 70 HIV-seropositive and 70 HIV-seronegative participants. Subjects reactive to either 
antigen were considered KSHV seropositive and analyzed for salivary KSHV DNA, which was 
quantified using primers for the K6 gene region. 
Results 
The demographic characteristics of the two groups were similar, with 36% males (median age, 
35yrs.) and 64% females (med. age, 34yrs.) in the HIV-positive group, and 31% males (med. 
age, 36.5yrs.) and 69% females (med. age, 36.5yrs.) in the HIV-negative group.  Of 70 HIV-
positive participants, 100% were black Africans, as was 97% of the HIV-negative group, with 
the remaining 3% being Indian/Asian and Mixed race.  Only 24% of HIV-positive patients 
were on Anti-retro viral treatment.  
 Fifty-four percent of all participants tested positive for KSHV, with 33% reactive to lytic K8.1, 
37% to latent Orf73 and 21% to both.  Of those HIV-positive, 50% were seropositive for K8.1 
and 46% for Orf73.  In those HIV-negative, 16% were seropositive for K8.1 and 29% for Orf73.  
The HIV-positive group demonstrated a significantly higher percentage KSHV seropositivity 
(70% vs. 37%, p=0.0001).   Amongst the KSHV seropositive participants, KSHV DNA was 
detected in 41 % HIV-positive and 23% HIV-negative participants. 
Conclusion  
KSHV seroprevalence was high in South African adults attending an urban HCT clinic. HIV 
positive status was associated with a higher KSHV seropositivity and a greater KSHV salivary 
shedding. HIV positive individuals should be tested for KSHV infection and those found 




CHAPTER 1. INTRODUCTION 
1.1 Introduction 
South Africa has the highest incidence of HIV/AIDS globally, with approximately seven 
million people infected, or 19.2% of the population, specifically those between the ages 
of 15 and 49. A number of conditions are known to be associated with those who are 
immune-compromised, specifically tuberculosis and other infectious conditions.  The 
incidence of various cancers is also reported to be above the norm in this population, 
notably Kaposi’s sarcoma (KS) an AIDS-defining cancer.  Of concern is the increased 
prevalence in reported cases of KS and it has been documented as a public health 
concern.  Kaposi’s Sarcoma-associated herpes virus (KSHV) also known as Human 
Herpesvirus type 8 (HHV 8) is the virus known to be aetiologically linked to KS. It is 
highly infectious and not treatable. With the limited research on the seroprevalence and 
viral quantification of this condition, it is difficult to evaluate the risk that the South 
African population is exposed to. 
This chapter presents the background to the study, and provides an overview of HIV 
prevalence and HIV related KS incidence.  The literature review gives insight into the 
history of KS and its associated causative virus, KSHV, along with the cyclic phases and 
replication.  In order to understand the ingenious survival of this otherwise dormant virus, 
it was important to study the transmission pathways documented from previous studies.  
Since endemic and epidemic KS exists, populations with high KSHV seropositivity 
globally, in Africa and South Africa are described.  This led to a more focused evaluation 
of KSHV/HIV co-infected population studies.   
 
1.2 Background 
Viral-associated cancers are common amongst HIV-positive individuals, especially in 
sub-Saharan Africa (SSA), which carries the  highest burden of disease[1].  In 2014, 
UNAIDS  estimated that 66% of those infected by the global HIV epidemic (25.8 million 
people) were in SSA, with 1.4 million new infections in that year.[1]  According to the 
South African National HIV Prevalence, Incidence, Behaviour and Communication 
Survey of 2012, there were 1.2 million more people living with HIV compared to 2008.  
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The overall HIV prevalence in the age group of 15-49 years in 2008 was 18.8%, with 
females having a higher infection rate than males in all age groups.[2]  In 2015, it was 
estimated that approximately 7 million individuals in South Africa were infected with 
HIV, with 380 000 being newly infected in that year.   
 
The province of KwaZulu-Natal (KZN) is the most affected, with an estimated 40% of its 
population being infected, and an HIV prevalence of 16.9%. Within this province the 
metropolitan eThekwini Municipality (Durban) has a prevalence of 14.5 %. [2, 3]  
KSHV, also known as Human Herpes Virus8 (HHV8), is implicated in the aetiology of 
KS [4, 5] a marker for advanced HIV/AIDS, and a WHO clinical stage 4 AIDS-defining 
illnesses.[6]   The HIV epidemic in SSA has been responsible for the increase in 
incidence of KS, with the incidence in endemic areas, having increased by 20-fold, 
making it the commonest cancer in males and second most common in females.[7]  The 
age-specific incidence of KS has also changed from being 59.7 year olds in 1983 to 36.5 
year in 2006.  It also mimics the trend of HIV incidence, with a sharp increase from 15 
years, peaking at 33-39 years of age.[7, 8]  
 
A cross-sectional study of KSHV in Johannesburg, South Africa, demonstrated a high 
prevalence among HIV-infected adults initiating antiretroviral therapy (ART), with 
almost half of the 404 participants being positive for the virus.[9]  The relationship 
between KSHV and HIV infection in Durban is however unknown, although previous 
studies suggest that uncontrolled HIV and lower CD4 counts may be associated with 
salivary shedding of KSHV, and thus potential infectivity.[8, 10, 11]  KZN continues to 
display a steadily increasing incidence of HIV [2], with  little documentation on its co-
infection with KSHV. Improving the knowledge of KSHV seroprevalence is central to 








1.3 Literature Review 
Kaposi’s sarcoma is a malignant vascular neoplasm which was first described by Dr. 
Moritz Kaposi in 1872. It affects the skin, mucous membranes, internal organs and lymph 
nodes.[12] The lesions associated with KS are histologically intricate and consists mainly 
of spindle-shaped cells, possibly of endothelial origin.[13] In addition, KSHV has been 
implicated in the aetiology of KS. [14, 15]  
Based on epidemiology and clinical characteristics, KS can be classified into four 
subtypes:  
 Classic KS: commonly occurs in elderly men of Mediterranean and Jewish descent 
who are HIV negative.[16] 
 Iatrogenic KS: occurs in patients who received solid organ transplants and those 
using prolonged immunosuppressive therapy.[17] 
 African endemic KS:  described in younger individuals mainly from Sub-Saharan 
Africa.[18]  
 Epidemic/ AIDS-related KS: an aggressive form of KS first described in a group of 
young HIV positive homosexual men in the United States of America 
(USA).[19]  
 
Since 1981, KS has emerged as an AIDS defining disease rather than just a previously 
known, uncommon malignancy. In its early stages, KS was the most frequent malignant 
tumour in HIV/AIDS patients, specifically amongst homosexual men.[20] Not all HIV 
patients presented with KS. The rapid rise in KS incidence prompted the search for a 
sexually transmitted causative agent. [21]  Chang, Moore and their collaborators provided 
some answers in 1994 with their discovery of short DNA sequences of a unique human 
herpes virus that was associated with KS in the dermis of a patient with AIDS.[14]  This 
gamma 2 herpes virus was called KSHV, and is considered to be the principal cause of 
KS, being  very similar to Epstein-Barr virus (EBV).   Since KSHV was discovered, its 
full genome has been cloned and its DNA sequence determined.[22]  Besides being the 
causal agent in the most common AIDS-defining malignancy, KSHV was subsequently 
determined to be a cause of other malignancies in patients with AIDS, including primary 
effusion lymphoma (PEL) and multicentric Castleman's Disease.[23, 24] 
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In the quest to uncover how KSHV is transmitted, scientists had to develop serologic 
assays to detect host antibody reactivity to the virus’s lytic and latent phases, and 
associated replication with polymerase chain reaction (PCR) assays.[25]  
 
1.3.1 Lytic and latent phases of KSHV   
Epidemiological studies for KSHV infection became possible with the development of 
serological assays, which enabled the detection of host antibody reactivity to KSHV.  
However, the antibody response to a KSHV infection was not fully understood, as the 
virus expresses proteins differentially.  This differential protein expression is dependent 
on whether the virus is in a latent or lytic phase of infection, hence the development of 
the first immunofluorescence assay (IFA) that could quantify both antibodies.  This test 
was found to be 90% sensitive. Unfortunately, the results for IFA did not correspond with 
other assays in HIV-positive patients with KS, and yielded a lower sensitivity of 75% for 
KSHV infected patients.[26, 27] The IFA was followed by the development of the 
enzyme immunoassays (EIAs), which were 100% sensitive and 95.8% specific, [28] 
making them a more reliable method of testing.   Many studies show the EIAs improved 
specificity with differing antigenic targets, including latent and lytic proteins, as well as 
whole viral lysates. Serological assays are based on expression of genes from the viral 
episomes and during latent KSHV infection phase, a limited number of genes are 
expressed: including viral cyclin D (orf 72), latency-associated nuclear antigens (LANA-
1 or orf 73) and viral Fas-ligand interleukin-1B-converting enzyme inhibitory protein 
(K13 or vFLIP).[29]  These genes serve several functions and when infected host cells 
are undergoing mitosis, LANA-1 facilitates the proliferation of viral episomes by 
assuring transcription through the attachment of KSHV DNA to the H1 histone on host 
chromatin.[30]  In combination, the 3 genes: orf73, LANA-1 and vFLIP control the host 
cell cycle, triggering tumourigenesis.  Furthermore, LANA-1 represses apoptosis by 
blocking the transcriptional activity of p53.[31]   The Fas death receptor pathway is 
hindered by vFLIP as it protects cells latently infected with KSHV from apoptosis.  The 
counteraction of the host cell cycle growth arrest controlled by cyclin-dependent kinases 
and pRb is executed by orf 72.[32] 
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The initiation of the lytic phase is dependent on the gene product orf 50 (Rta), which is 
similar to the lytic phase of other human herpes virus, where gene products are 
manufactured sequentially, i.e. the initial genes articulate subsequent gene expression.  
This is followed by DNA replication genes, and finally those responsible for virion 
production and genes encoding homologues of cellular proteins.[33]  Once in this phase, 
the viral titre increased in the host and quantifying KSHV viral loads was possible using 
quantitative PCR assays. 
  
1.3.2 KSHV Viral Load 
Viral quantification of KSHV, an important indicator for KS progression, can be 
performed on DNA extracted from peripheral blood mononuclear cells (PBMC), a biopsy 
of KS lesions and salivary samples.[34-36] KSHV viral load quantification has been used 
in many studies for different reasons. In a Spanish study viral loads were performed to 
understand the routes of transmission, where 200 women (100 female prostitutes and 100 
random females from the general population) were evaluated.  KSHV DNA was detected 
in 3% of oral cavity samples, in 2% of cervical samples of prostitutes and 1% of the 
general female population.  This showed that oral shedding and heterosexual contacts are 
potential pathways of transmission.[37]  
 
In some studies KSHV viral loads have been used to show associated increased KS risk, 
with those who were K8.1 seropositive, having a tenfold higher increase in KSHV 
viremia.[7, 38] An important HIV co-infection study in Uganda showed that among 74 
HIV-positive patients, KSHV DNA was detected in the PBMCs of 93% of patients and 
quantified in 77% thereof.  The KSHV viral load was higher in men than women and 
those with faster (>20 lesions per year) rate of KS lesion eruption.  It also showed that 
KSHV load was unrelated to CD4 lymphocyte count.[39]  In a Kenyan study, high 
KSHV seroprevalence and quantities of oral KSHV shedding were observed in a cohort 
of woman.  Their findings supported the observation that oral replication is an important 
factor for KSHV infection, with likely implications of KSHV transmission and KS 




  1.3.3 KSHV Transmission 
Many studies have been conducted in an attempt to understand AIDS-associated KS and 
its transmission by trying to detect for KSHV in PBMCs, plasma, genital and oral 
secretions.[36, 40]  It appears that the mode of transmission is still a highly debatable 
issue, with saliva most commonly harbouring KSHV, thus being considered an important 
channel for transmission.[41-47] 
In the USA, a study conducted by the National Health and Nutrition Examination Survey 
III sampled 13,894 individuals from the general population with an enzyme assay to 
measure KSHV antibodies.  KSHV transmission amongst men occurred through sexual 
activity, especially in men having sex with other men (MSM), with no conclusive 
evidence being found for heterosexual transmission to women.[48] A study in Nigeria 
indicated risky sexual behaviour as enabling KSHV transmission amongst men and 
women.[49] 
 
Horizontal non-sexual transmission has been increasingly supported and accepted, with 
qualitative analysis in a KZN study finding 14 possible practices that expose children to 
saliva, and therefore at risk of KSHV transmission.  Of the 14, no single method was 
indicated as more important.  However, the positive aspect of this study is that it can be 
used to educate female caregivers in preventing transmission of KSHV to children.[50]   
 
Further investigation of KSHV seroprevalence was carried out in high risk population 
like those infected with HIV in order to find other links in viral transmission.  
 
1.3.4 Global KSHV Seroprevalence and HIV co-infection 
The incidence of KS and KSHV seroprevalence has geographical and sub-population 
variation.   KSHV seroprevalence in the general population of HIV-negative individuals 
in northern Europe, Asia and the USA is less than 10%, is 10-30% in the Mediterranean, 
and greater than 50% in Sub-Saharan Africa.[51]  A study from various regions in Italy 
of 747 healthy blood donors displayed 13.8% KSHV infections.[52]  A seroprevalence 
study of KSHV in Southeast Asia,  the USA, the Caribbean, and Africa reported it to be  
low in healthy and HIV-positive individuals in the first two, which correlated with low 
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reports of AIDS-related KS.[53]  A study in the Shandong area of China showed that 
16.3% (14/86) of HIV-positive patients were KSHV positive compared to the 5.7% in 
230 healthy blood donors who were negative.[54] This highlights the importance of HIV 
as a cofactor for the development of KS in the setting of KSHV infection. The KS 
incidence in the general population is 1 in 100 000, but with HIV-infection it is 1 in 20 
[55]  and higher in MSM with almost 1 in 3.[56] 
 
1.3.5 KSHV and HIV co-infection in MSM 
A study in San Francisco, USA, in a population of 593 MSM in an area with a high 
incidence of HIV reported that 37.6% were KSHV-positive.[20]  A retrospective study in 
the USA also supported the observation that KSHV and manifestations of KS are most 
frequently seen in HIV-positive homosexual men.[57] A 30-month follow-up was also 
performed in 75 men and showed KS development in two.[57]  In a Danish study 
initiated in 1981, 21.1% (52/246) of homosexual men were KSHV seropositive.[48]  An 
Amsterdam cohort study of 1458 homosexual men indicated the incidence of KSHV to 
be 20.9% (305/1458) being highest in the HIV-positive group.[58]  For many years it was 
observed that KSHV infections were more prominent in homosexual men, however, with 
the development of the HIV/AIDS pandemic, the rates of KSHV infection have increased 
in heterosexuals as well.[49, 59]  
 
1.3.6 KSHV and HIV co-infection in Africa 
In Ghana, West Africa, a cohort of 3275 HIV-seronegative healthy blood donors 
displayed 23.7% positivity for KSHV, and 65.6% from 250 HIV/AIDS patients.[60] 
African countries such as Ghana, Uganda, and Zambia showed increased seroprevalence 
of KSHV in both healthy and HIV-positive individuals, with Uganda at 38.7% (24/62) in 
HIV-negative and 45.7% (16/35) in HIV-positive patients.[53]    In contrast to Uganda, 
South African children had a seroprevalence of 7.5% - 9% and the KSHV seroprevalence 
did not increase with the age of the children.[61]  It was also evident in a KSHV 
transmission study that the risk of South African children acquiring KSHV was higher for 
those who had KSHV seropositive mothers and the HIV status of the mothers was 
marginally associated with an elevated risk of KSHV seropositivity in their children.[62]   
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Determining the mode of transmission from mother to child has been a standing question 
as studies to support vertical transmission (during birth and breastfeeding) have been 
limited.[63] 
 
1.3.7 KSHV Seroprevalence and HIV co-infection in South Africa 
Studies conducted thus far have focused on areas of Africa where KS is endemic.[64]   
The HIV epidemic has highlighted KS in South Africa, where an increased number of 
cases have been reported.  A Durban cancer prevalence study of 152 patients with HIV-
associated KS showed an equal female to male ratio, with more severe disease in younger 
females.[65]  A retrospective study in KZN showed that age-standardized incidence 
increased from 1:100 000 in 1990 to 15:100 000 in 2006.[8]   
Studies in KZN of KSHV seroprevalence have focused mainly on mother-child pairs in 
trying to understand the transmission of the disease.  In a cohort of 427 children, 7.5-
9.0% were KSHV positive by testing for antibodies.[61]  In an earlier study in the 
Hlabisa District, north of Durban, 34.6% of 136 patients who were randomly tested for 
antibodies against KSHV tested positive.[66]  In a later study in the  Hlabisa district, 
2546 mother-child pairs were tested for latent and lytic antigens to KSHV.  Mother-child 
lytic antigens were higher (40%-12%) than the latent antigens (14%-7%)  as was their 
HIV prevalence at 28% and 22%, respectively.[67]  
   
Further north in the Gauteng Province, in the areas of Johannesburg and Soweto, a cancer 
prevalence study showed that 36.3% (1196/3293) of patients were KSHV positive via the 
immunofluorescence assay.  This study also showed that the prevalence of KSHV 
antibodies increased with increasing age and sexual partners, and was not strongly related 
to HIV infection.[68]  Another South African study aimed at understanding the 
transmission of KSHV as well as other co-infections and lifestyle factors, recruited 
pregnant women from 37 clinics in Gauteng. In that cohort of 1740 woman, 44.6% were 
KSHV seropositive.  These women were four times more likely of being HIV-positive as 
well. [69] Another South African study recruited pregnant women from 37 clinics in 
Gauteng, to understand transmission of KSHV, as well as other co-infections and lifestyle 
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factors.  In that cohort of 1740 woman, 44.6% were KSHV seropositive, with those being 
four times more likely of being HIV-positive as well.[69]  
     
One of the later studies in Johannesburg looked only at HIV-positive patients who had 
not initiated ART.  Of the 404 patients screened for lytic and latent KSHV antibodies, 
43% (193/404) were positive.[9]  There are no studies comparing the seroprevalence of 
KSHV in an HIV-positive versus HIV-negative population in KwaZulu-Natal, South 
Africa. The province is the epicenter of the HIV epidemic in the country making it 
important to investigate the extent of the co-infection with KSHV. 
 
1.4 Problem Statement 
The combination of KSHV/KS and HIV/AIDS has detrimental outcomes for the dually 
infected patients.  South Africa is one of the highest HIV burden countries, with KZN 
being the worst affected. The prevalence of HIV/KSHV co-infection in KZN adults has 
not been established and determining this will assist us in earlier identification of those at 


















CHAPTER 2. METHODOLOGY 
 
2.1 Aim and Objectives 
The study aimed to establish the seroprevalence of KSHV in an adult population in 
Durban, KwaZulu-Natal Province. 
 
The study had the following objectives: 
1. To establish participant HIV status and medical history. 
2. To quantify the antibodies against lytic (K8.1) and latent (LANA) KSHV encoded 
proteins of the HIV-positive and HIV-negative participants. 
3. To evaluate KSHV salivary shedding through a cell associated KSHV viral loads 
in subjects who were KSHV-seropositive by quantitative real-time PCR. 
 
2.2 Study design 
This was a cross-sectional seroprevalence study conducted between July and October 
2013.  The site HIV Counselling and Testing (HCT) counsellors explained the study with 
reference to an information sheet (Appendix I).  Where necessary a verbal translation in 
the native language of the participant was used to explain along with translated 
information sheets (Appendix II).  The counsellor then referred patients to research 
nurses who obtained the signed informed consent (Appendix III) with native language 
translation where necessary (Appendix IV).  The nurse interviewed the patient in order to 
evaluate eligibility criteria and completed the data sheet (see Appendix V).  The eligible 
candidates were screened for HIV with dual HIV rapid tests.  Specimens were collected 
with a tracking laboratory form (Appendix VI).  A single 5ml venous blood draw in a 
serum separating tube was obtained as well as a non-invasive mouthwash for saliva 
specimen collection.   
 
 
2.3 Study Site and population  
This study took place at an HIV counselling and testing (HCT) clinic in a public sector in 
Durban, the largest city in KZN province. The clinic serviced local community with 
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regard to voluntary counselling and testing.  ART and palliative care were offered and 
those individuals who were HIV-positive and not at a critical stage to receive treatment 
would have returned for repeat CD4 counts and HIV viral load quantification.  The clinic 
was involved in AIDS treatment program.  These participants were not in any clinical 
trial.  Two independent proportion (null case) power analysis was done using the two-
sided Fishers exact test to calculate sample size.   Based on the assumption that 40% of 
the HIV-positive group will be KSHV-positive and 10 % HIV-negative group will be 
KSHV-positive, a sample size of 36 per group would achieve an 80% power to detect a 
difference between the two groups. The sample size was doubled and included 70 HIV-
positive and 70 HIV-negative adult individuals. 
  
The following inclusion criteria applied: 
1. Male/ female participants of any race 
2. 18 years and older 
3.   Screened HIV status available 
4. Agreed to provide whole blood and salivary specimens 
5. Voluntary agreement to participate and from whom signed informed consent was 
obtained. 
 
The following exclusion criteria applied: 
1. Participants under 18 years of age 
2. Refusal to provide whole blood and salivary specimens 











2.4 Data and Clinical specimen collection: 
Participants were screened for HIV by a dual rapid HIV testing system to determine HIV 
prevalence in this population.  The two preferred HIV rapid testing kits used were 
AbonTM HIV Tri-Line Rapid test and First Response HIV 1-2.0 Card Test of which 
detected for HIV-1 and HIV-2.   Both HIV-positive and HIV-negative patients were 
secured for the study. They were asked to provide a sample of blood and saliva as part of 
the study.  A single 5ml venous blood draw was collected in serum separator tubes (SST) 
to quantify the antibodies against lytic (K8.1) and latent (LANA) KSHV encoded 
proteins, and a non-invasive mouth wash for saliva specimen collection to quantify 
KSHV salivary shedding through a cell associated KSHV viral loads in subjects who 
were KSHV-seropositive.  The SST’s were centrifuged and serum transferred into 
labelled cryovials where they were stored in an ultra-freezer until testing.  Saliva samples 
were centrifuged to obtain a pellet of oral cells.  The pellet and supernatant were stored in 
labelled cryovials, in an ultra-freezer.  The HIV-positive patients were requested to 
provide their last known CD4 count and HIV viral load results, as well as information 
regarding their ART. 
 
2.4.1.  
Objective 1: To establish HIV status and medical history of participants.  
The HIV screening was performed at the clinic site and results were recorded to evaluate 
the HIV prevalence.  Whole blood from a finger prick was used on the rapid testing kits, 
AbonTM HIV Tri-Line Rapid test and First Response HIV 1-2.0 Card Test in accordance 
to the package insert instructions.  AbonTM HIV Tri-Line Rapid test is 99.9% sensitive 
and 99.8% specific in detecting anti-HIV-1 including subtype O and anti-HIV-2 
antibodies.  The reading of a control line and either one or both of the test lines was 
regarded as a reactive result whilst just a control line was non-reactive.   An invalid test 
was that without a control line irrespective of appearance of any of the test lines. 
      
The First Response HIV 1-2.0 Card Test is 100% sensitive and 99.9% specific in 
detecting anti-HIV-1 including subtype O and anti-HIV-2 antibodies.  The reading of a 
control line and either one or both of the test lines was regarded as a reactive result whilst 
13 
 
just a control line was non-reactive.   An invalid test was that without a control line 
irrespective of appearance of any of the test lines.  These results were recorded and 
attached onto data sheets, which not only provided demographic information, but also 
other illnesses that participants may have been experiencing as well as treatments they 
were receiving.  Characteristics of age, gender, ethnic groups and employment status 
were documented.  HIV-positive participants were required to provide last known, if any 
CD4 counts, HIV viral loads, and ART for their data sheet entries. 
  
2.4.2  
Objective 2: To quantify the antibodies against lytic (K8.1) and latent (LANA) KSHV 
encoded proteins of the HIV-positive and HIV-negative participants. 
Serum was used to detect dual antibodies to KSHV by serologic assays.  Optical density 
(OD) measurements to latent nuclear antigen (LANA) encoded by Orf73 as well as the 
lytic phase glycoprotein K8.1.  A method adapted from previously described 
literature.[28]    Positive and negative controls were triplicates in a 96-well plate along 
with triplicates of each participant’s serum samples.  The serum samples for the Orf73 
assay were initially diluted 1:100 in assay buffer.  The OD was measured at 630nm with 
the BMG Spectrostar Nano (Orthanberg, Germany).  The results for the Orf73 and K8.1 
assay were analyzed, adhering to assay cut off, titration and quality controls.  The OD 
values falling below the negative cut-off line were regarded as seronegative whilst those 
falling above the positive cut-off line were regarded as seropositive.  The OD values 
falling between the positive and negative cut off lines were indeterminate. Subjects who 
were K8.1 and/or LANA seropositive were regarded KSHV seropositive.  GraphPad 
Prism 5 statistical software package was used thus to determine significance of results 
between HIV-positive and HIV-negative groups. 
 
2.4.3  
Objective 3: To quantify KSHV salivary shedding through a cell associated KSHV viral 
loads in subjects who were KSHV-seropositive. 
 Saliva samples were pelleted to obtain oral endothelial cells.  The DNA was extracted 
using a QiagenQiAamp DNA mini extraction kit.  The DNA quality and cell quantitation 
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were determined using real-time PCR for endogenous retrovirus 3 (ERV3) whilst the 
KSHV DNA was quantified using probes and primer that amplified the K6 region (viral 
macrophage inflammatory protein α).  The KSHV Probe (p-K6-10) 5’-[FAM] 
CACCCACCGCCCGTCCAATTC [TAMRA]-3’, forward primer (K6-10F) 5’-
CGCCTAATAGCTGCTGCTACGG-3’ and reverse Primer (K6-10R)  
5’TGCATCAGCTGCCTAACCCAG-3’ was used on the Roche LightCycler 480 PCR 
platform.  The ERV3 and K6 standard curves were optimized.  KSHV viral load was 
extrapolated, calculated and reported as KSHV copies per million (106) cells. 
 
2.5 Data Analysis –to interpret the resulting data collected from data sheets and 
laboratory assays 
The participants’ demographics were extracted from the data sheets and stratified by HIV 
status and summarized as simple proportions or medians. GraphPad Prism 5 statistical 
software package was used to determine any significance between the HIV-positive and 
HIV-negative groups.  Unpaired t test was used to determine the prevalence odds ratio 
(OR) for KSHV infection and 95% confidence intervals (CI).  Statistical analysis of the 
lytic and latent assays was performed using unpaired t test with software GraphPad Prism 
5 to show significant difference between the HIV-positive and negative groups. 
For KSHV salivary shedding, the ERV3 (endogenous retrovirus 3) and K6 (viral 
macrophage inflammatory protein α) standard curves were optimized, shown in Figure 
S1 and Figure S2, respectively (Supplementary Figures).  KSHV viral load was 
extrapolated, calculated and reported as KSHV viral copies per million (106) cells.  
Subjects were categorized as “non-shedders” (KSHV not detectable in saliva), “low 
shedders” (KSHV detectable at <3,000 copies/106 cells), or “high shedders” (KSHV 
>3000 copies/106 cells) for comparisons between groups. Additionally, the KSHV viral 
loads for each group was averaged and variance between the two groups (HIV-positive 







2.6 Data Management 
Information from all data sheets for each participant was captured by the PI onto 
Microsoft Excel Spreadsheet on a password protected PC.  The actual data sheets and 
HIV screening results are filed and locked away. 
ELISA results for both lytic and latent assays were exported in Microsoft Excel format 
from the BMG Spectrostar Nano and stored with patient data sheet information. 
Quantitative real time PCR results for KSHV viral quantification were exported from the 
Roche LightCycler and stored with patient data sheet information.  
All biological specimens remaining after testing are stored in a secured ultra-freezer until 
completion of the study. 
 
2.7 Ethical considerations 
This study was only conducted at the specified site and ethical clearance was obtained 
before commencement of any work. 
Ethical clearance reference: BE 194/010 
Participants were reimbursed for their traveling costs in accordance with:  
1) Guidelines for Good Practice in the Conduct of Clinical Trials in Human Participants 
in South Africa – Department of Health (2006), and  
2) Ethics in Health Research: Principles, Structures, and Processes – (2004). 
Potential risks (none in this study) and discomforts (small blood draws) were explained 
clearly. 
The onsite designated study personnel explained the study to the subject, who had the 
opportunity to review it and ask any questions. All subjects signed the informed consent. 
A copy was given to the subject and a copy filed for official purposes. 
To maintain patient confidentiality, patients’ identity was not on the data sheet but 








CHAPTER 3. RESULTS 
 
3.1 Introduction 
This chapter presents the results of the study with respect to the study objectives. The 
participants HIV status and demographics are followed by medical history, with some 
insight into any treatments received, especially ART for HIV-positive patients.  The 
KSHV seroprevalence was established by laboratory testing the serum, processed from 
whole blood specimens collected at the clinic, and  the differences and variances seen 
within and between the HIV-positive and HIV-negative individuals is indicated. KSHV 
salivary shedding was established through cell associated KSHV viral loads in subjects 
who were KSHV-seropositive.  KSHV DNA was amplified from processed saliva 
specimens collected at the clinic.   
 
3.2 Objective 1:  To establish participants HIV status, medical history and 
demographic data 
At the end of enrolment, 140 participants were enrolled for the study by adhering to the 
inclusion/exclusion criteria.  After establishing HIV status with the rapid test results, 
participants were divided into HIV-positive and HIV-negative groups.  Their 
demographic data and medical history are presented in Table 3.1. Of the 70 HIV-positive 
participants, 25 (36%) were males, with ages ranging from 26 to 53 years old, and a 
median age of 35years.  Females accounted for 45 (64%), with ages ranging from 22 to 
56 years old, and a median age 34 years.  In the HIV-positive group, 49% were 
employed, 40% were unemployed, and 11% did not state employment.  All 70 of the 
HIV-positive were Black Africans, of whom 24% were on ART, which included first line 
therapy of either regimen 1 or 3TC (Lamivudine: a nucleoside reverse transcriptase 
inhibitor), TDF (Tenofovir Disoproxil Fumarate: a non-nucleoside reverse transcriptase 
inhibitor) and EFV (Efavirenz: a non-nucleoside reverse transcriptase inhibitor).  Two 
male participants documented a history of a sexually transmitted infection (STI) and a 





Table 3.1: Participants HIV status, demographics and medical history 
Variable Characteristics HIV positive 
N (%) (n=70) 
HIV negative 
N (%) (n=70) 
Gender Male 25 (36%) 22 (31%) 
Female 45 (64%) 48 (69%) 
Age  
Median (range) 
Male  35yrs (26-53) 36.5yrs (23-58) 
Female 34yrs (26-56) 36.5yrs (18-77) 
Employment status 
N (%) 
Employed 34 (49%) 44 (63%) 
Unemployed 28 (40%) 8 (11%) 
Not stated 8 (11%) 18 (26%) 
Race Black African 70 68 
Coloured - 1 
Indian - 1 
Medical history  
Anti-retro viral treatment Male 5 (7%) - 
Female 12 (17%) - 
Sexually transmitted 
Infection 
Male 2 1 
Female - - 
Tuberculosis Male - - 
Female 1 - 
Asthma Male - - 
Female - 1 
- denotes no applicable information 
Of the 70 HIV-negative participants, 22 (31%) were males, with ages ranging from 23 to 
58 years old, and a median age of 36.5years.  The number of females was 48 (69%), with 
ages ranging from 18 to 77 years old, and a median age 36.5 years.  In the HIV-negative 
group, 63% were employed, 11% were unemployed and 26% did not declare their 
employment status.  Sixty-eight participants in this group were Black Africans, 1 mixed 
race and 1 was Indian/Asian.  One male had documented history on an STI and a female 
of asthma.  
 
3.3 Objective 2. To quantify the antibodies against lytic (K8.1) and latent (LANA) 
KSHV encoded proteins of the HIV-positive and HIV-negative participants  
K8.1 and LANA seroreactivity were evaluated both individually and together. 
Participants reactive to either or both viral proteins were considered KSHV seropositive. 
Regarding the Lytic (K8.1) assay, the OD values were plotted and graphs extrapolated in 
















Figure 3.1:  Lytic K8.1 ELISA assay for HIV-positive vs. HIV-negative participants 
showing optical density values per participant. 
 
Of the 70 participants in the HIV-positive group, 50% (35/70) were seropositive for K8.1 
ELISA, 49% (34/70) were negative and 1% fell into the indeterminate category. Of the 
70 participants in the HIV-negative group, 16% (11/70) were seropositive for K8.1 
ELISA, 83% (58/70) were negative and 1% fell into the indeterminate category. 
 
A comparison of the lytic assay between the two groups in Figure 3.2 indicated that 50% 
(35/70) of HIV-positive patients were KSHV seropositive whilst only 16% (11/70) HIV-
negative patients were KSHV seropositive.  The HIV-positive group showed 49% (34/70) 
seronegativity and the HIV-negative group 83% (58/70), with a 1% indeterminate in both 
groups.  HIV-positive group reported a significantly higher percent of participants with 
KSHV lytic antibody as compared to the HIV-negative group (p-value <0.0001, 95%CI, 
0.378 to 0.825).   


































Figure 3.2: Number of participants reactive to the lytic K8.1 antigen and reported as 






































Latent ORF73 ELISA Assay 
 














Figure 3.3:  Latent Orf73 ELISA assay for HIV-positive vs. HIV-negative participants 
showing optical density values per participant. 
 
A comparison of the latent assay between the two groups in Figure 3.4 showed that 46% 
(32/70) of the HIV-positive group were seropositive for latent antibodies and 54% 
(38/70) were seronegative.  The HIV-negative group showed 28% (20/70) were 
seropositive, 64% (45/70) were seronegative whilst 8% (6/70) remained indeterminate.     
A significantly higher percentage of HIV-positive participants were positive for the latent 
KSHV antibody compared to those that were HIV-negative (p-value=0.0251, 95%CI, 











































Figure 3.4: Number of participants reactive to the latent orf73 antigen and reported as 








































KSHV Seropositivity: Combined lytic and latent results 
Results of the K8.1 and Orf73 assays were combined to give a final qualitative outcome    



















Figure 3.5:  Combined lytic and latent ELISA results for HIV-positive vs. HIV-negative 
participants.   
 
Total cohort Seroprevalence:  
Seroprevalence for the entire cohort was calculated to be 54% (75/140) positive for 




































The combined outcome of both the lytic and latent assays demonstrates that 70% (49/70) 
of HIV-positive participants were classified as KSHV-positive and 30% (21/70) as 
KSHV-negative.  Whilst 37% (26/70) of the HIV-negative participants were KSHV-
positive, 54% (38/70) were KSHV-negative and 9% (6/70) were indeterminate.  Overall, 
HIV-positive participants had a significantly higher percentage KSHV positivity 
compared to those who were HIV-negative (OR=3.41, p-value=0.0009, α <0.05).   
 
Of the 70 HIV-positive participants, 20 males and 29 female were KSHV positive 
compared the 10 males and 16 females of those HIV-negative (Figure 3.6). The overall 
KSHV seropositivity for males was 40% (30/75) compared to 60% (45/75) for females 
amongst the KSHV seropositive individuals.  The proportion of males and females 
KSHV seropositive within the total cohort was 21.4% (30/140) vs 32.1% (45/140), 
respectively.  Although there was no significant difference between KSHV seropositivity 
in males and females with regards to the participant numbers of the HIV-positive and 
HIV-negative groups, there were differences observed in lytic and latent antibody 













Figure 3.6:  KSHV seropositivity of males vs. females in the HIV-positive and HIV-











































Figure 3.7:  Comparison of lytic and latent ODs for HIV-positive and HIV-negative  
male vs. female. 
 
The HIV-positive/lytic-positive males accounted for 20% (14/70) compared to the 30% 
(21/70) in females, while the latent-positive males were 21.4% (15/70) and the females 
21.4% (15/70).  The HIV-negative/lytic-positive males were 7% (5/70) compared to the 
females’ 8.6% (6/70), while the latent-positive males accounted for 12.9% (9/70) 
























































































































Table 3.2:  Comparison of KSHV positive Male and Females in the HIV-positive 
and HIV-negative groups 
Grouping Comparison Lytic/Latent antibodies Significance P value 
HIV-positive & HIV-negative males vs. 
females 
Lytic vs Latent antibody Yes 0.0008 
Lytic antibody Yes 0.0067 
Latent antibody Yes 0.0138 
HIV-positive males vs. females Lytic antibody No 0.2808 
Latent antibody No 0.4381 
HIV-negative males vs. females Lytic antibody No 0.0964 
Latent antibody Yes 0.0282 
Male HIV-positive vs. male HIV-negative Lytic antibody Yes 0.0004 
Latent antibody Yes 0.0225 
Female HIV-positive vs. female HIV-negative Lytic antibody No 0.0656 
Latent antibody No 0.1619 
 
The statistical comparison using 1 way ANOVA of lytic versus latent antibody 
expression between males and females of the HIV-positive vs HIV-negative groups 
showed a significant difference between the means (p=0.0008), as well as a significant 
difference between the variances in the groups (p<0.0001, Bartlett’s test for equal 
variance).  A combination of male and female lytic antibody expression was marginally 
higher in mean and variance in the HIV-positive than the HIV-negative group 
(p=0.0067).  A combination of male and female latent antibody expression was 
marginally higher (p=0.0138) in the HIV-negative group, including a higher variance 
(p=0.0016).  Within the HIV-positive group, there was no significant difference between 
the males and females with respect to the lytic and latent antibody expression.  However, 
there was a noticeable difference in the latent antibody expression between the males and 
females in the HIV-negative group. Male latent antibody expression was higher in the 
HIV-negative group (p=0.0282).   The HIV-negative males latent antibody expression 
was also higher than the HIV-positive males (p=0.0225), including a significant variance 
(p=0.0003).  The lytic antibody expression in HIV-positive males was significantly 
higher than HIV-negative males (p=0.0004).  The females did not show any difference in 
lytic or latent expression with regards to HIV status, although a slightly higher variance 




3.4 Objective 3:  To evaluate KSHV salivary shedding through cell associated 
KSHV viral loads in those who were KSHV-seropositive  
Salivary samples of the 49 HIV-positive and 26 HIV-negative participants who were 
seropositive for KSHV antibodies were used to detect KSHV DNA, with an additional 4 
samples that were randomly selected from the indeterminate KSHV category. This data is 


















Figure 3.8:  KSHV viral load (VL) quantification of HIV-positive and HIV-negative 




















































































Figure 3.9:  KSHV VL quantification of HIV-positive and HIV-negative participants, 










































































































































Figure 3.10:  KSHV viral load (VL) quantification of HIV-positive and HIV-negative 




























































































Figure 3.11:  KSHV VL quantification of HIV-positive and HIV-negative participants 
























































































Variable (Median)  
KSHV Shedding Category 
Not Detectable–
“Non Shedders” 






















Age (35) (Range: 36-53) 36.5 36 32 37 30 29 
KSHV VL (51copies/106cells) 
(Range: 1 - 2.1x1011 copies/106cells) 
* * 1.4x100 3x100 7.20x109 4.91x106 
K8.1 OD (1.623)  
(Range: 0.094- 2.984) 
0.985 1.356 1.695 1.932 1.956 1.623 
Orf73 OD (1.452)  
(Range:0.048- 2.236) 
1.538 0.570 1.459 1.758 1.536 1.186 
* denotes undetectable KSHV VL 




Variable (Median)  
KSHV Shedding Category 
Not Detectable–
“Non Shedders” 




















Age (39) (Range: 22-77) 32 42 45 41 38 
KSHV VL (9.5copies/106cells) 
(Range: 2 – 9.7x104 copies/106cells) 
* * 2.7x100 1.4x101 9.7x104 
K8.1 OD (0.536)  
(Range: 0.072- 1.750) 
0.617 0.456 1.279 1.288 1.512 
Orf73 OD (1.176)  
(Range: 0.041- 2.860) 
1.815 1.143 1.648 0.535 2.860 
* denotes undetectable KSHV VL 
31 
 
Of the 75 individuals, regardless of HIV status, who were KSHV seropositive, 50 
(66.7%) had an undetectable viral load while KSHV DNA was detected in 26 (34.7%).  
Of those, 19 had a low positive (<3000 KSHV copies/106 cells) and seven had a high 
positive viral load (>3000 KSHV copies/106 cells).  
Of the 30 HIV-negative participants (Table 3.4), KSHV DNA was detected in six 
samples.  The KSHV viral load ranged from 2 to 97 000 KSHV copies per 106 cells, with 
the median viral load of 9.5 KSHV copies/106 cells and an average viral load of 1.6 x 103 
KSHV copies per 106 cells.  There were seven males and 14 females in the “not 
detectable – non shedder” category with median ages of 32 years and 42 years, 
respectively.  The median OD for lytic K8.1 and latent Orf73 for males within this 
category was 0.617 and 1.815, respectively.  The median OD for lytic K8.1 and latent 
Orf73 for females within this category was 0.456 and 1.143, respectively.  There were 
two male and three females in the “low positive – low shedder” category with median 
ages of 45 years and 41 years, respectively.   The median OD for lytic K8.1 and latent 
Orf73 for males within this category was 1.279 and 1.648, respectively.  The median OD 
for lytic K8.1 and latent Orf73 for females within this category was 1.288 and 0.535, 
respectively.   One male in the “high positive – high shedder” category, aged 38 years 
had an OD for lytic K8.1 and latent Orf73 of 1.512 and 2.860, respectively.  There was 
no significant difference in means or variance between the “not detectable”, “low 
positive”, and “high positive” OD values of HIV-negative participants.  
 
Of the 49 HIV-positive participants (Table 3.3), KSHV DNA was detected in 20 samples.  
The KSHV viral load ranged from 1 to 2.0 x 1011 KSHV copies per 106 cells, with the 
median viral load of 51 KSHV copies/106 cells and an average viral load of 1.13 x 1010 
KSHV copies per 106 cell.  There were 12 males and 17 females in the “not detectable – 
non shedder” category, with median ages of 36.5 years and 36 years, respectively.  The 
median OD for lytic K8.1 and latent Orf73 for males within this category was 0.985 and 
1.538, respectively.  The median OD for lytic K8.1 and latent Orf73 for females within 
this category was 1.356 and 0.570, respectively.  There were five male and nine females 
in the “low positive – low shedder” category with median ages of 32 years and 37 years, 
respectively.   The median OD for lytic K8.1 and latent Orf73 for males within this 
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category was 1.695 and 1.459, respectively.  The median OD for lytic K8.1 and latent 
Orf73 for females within this category was 1.932 and 1.758, respectively.   There were 
three males and three females in the “high positive – high shedder” category with median 
ages of 30 years and 29 years, respectively.   The median OD for lytic K8.1 and latent 
Orf73 for males within this category was 1.956 and 1.536, respectively.  The median OD 
for lytic K8.1 and latent Orf73 for females within this category was 1.623 and 1.186, 
respectively.  The “low positive” and “high positive” OD values were significantly higher 
(p=0.0209) than the “not detectable” of the HIV-positive participants. 
 
The viral load variance between the HIV-positive and HIV-negative groups was 
significant (p-value < 0.0001), with a higher KSHV viral load in the HIV-positive 
participants, making them 3.6 times more likely to shed KSHV. Nine of the 29 
individuals from the “not detectable” KSHV shedding category (Table 3.3) were on ART 
(5 males and 4 females), as well as an additional female from the “low positive”.   This 
subgroup of 10 participants was further analyzed in Table 3.5 against other HIV-positive/ 
KSHV-negative participants on ART.   
  
In the HIV-positive group, 17 participants were on ART, with 10 of these KSHV 
seropositive.  Of these 10 participants, nine had an undetectable KSHV viral load, while 
only one female had a low KSHV viral load of 0.2 KSHV copies/106 cells (881 KSHV 
copies, not ERV3 corrected).  Two KSHV/HIV-positive males had CD4 counts of 218 













Table 3.5: Participants on ART 
Variable KSHV-positive/HIV-positive KSHV-negative/HIV-positive 
Gender (n) Male (5) Female (5) Male (1) Female (6) 
Age (Range) 39 (35-53) 37 (33-43) 37 39.5 (29-52) 




2.753           
(1.149-2.984) 






0.102           
(0.074-0.264 




218 and 500 * * 340 
HIV Viral load * * * Undetected 
ARV Treatment Regimen1 3TC, TDF, EFV * Regimen1, 3TC, 
TDF, EFV 
Other Illness STI TB STI Heartburn 
*denotes unavailable information 
Seven participants were in the KSHV-negative/HIV-positive category (1 male and 6 
females), with one female’s CD4 count of 340 cell/mm3 and an undetected HIV viral 
load.  The ART received in this group was also regimen 1 or 3TC, TDF, and EFV.  All 
participants were first visits to the HCT clinic thereby limiting data for HIV-positive 










The finding of this cross sectional study of adults in the eThekwini district of Durban, 
Kwazulu-Natal was that (54%) of the 140 participants tested positive for KSHV, with 
33% being reactive to lytic K8.1, 37% to latent Orf73 and 21% to both.  Of the HIV-
positive group, 50% were seropositive for K8.1, and 46% for Orf73.  In the HIV-negative 
group, 16% were seropositive for K8.1 and 29% for Orf73.  The HIV-positive group 
demonstrated a significantly higher percentage KSHV seropositivity (70% vs 37%, 
p=0.0001).   
 
Participants who were reactive to either lytic or latent antigens were analyzed for KSHV 
DNA.  Of those who were KSHV seropositive, 70% were HIV-positive and 37% were 
HIV-negative.   The KSHV DNA was detected in 41% HIV/KSHV-positive specimens 
with a viral load range from 1 to 2.0 x 1011 KSHV copies per 106 cells, two-thirds of 
whom were classified as low “viral shedders” and a third as high “viral shedders”.  Of the 
HIV-negative/KSHV-positive subjects, viraemia was detected in 23% specimens, with a 
load range from 2 to 97 000 KSHV copies per 106 cells with only one subject classified 
as a high “viral shedder”.    Only 24% of HIV-positive participants were on ART, 14% of 
those were KSHV seropositive with one low “viral shedder”.  The remaining 10% were 
KSHV seronegative.   
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CHAPTER 4. DISCUSSION 
4.1 Introduction 
This chapter discusses the findings of this study in comparison to other local and global 
studies. This chapter starts by discussing the participants’ demographic details, after 
which the findings of each objective are addressed.  The discussion includes the results of 
similar studies conducted in other provinces of South Africa, as well as in other countries.  
 
4.2 Objective 1:  To establish participants HIV status and medical history- 
demographic data  
The demographic details of the HIV-positive and HIV-negative groups were comparable 
with regards to the number and age.  A study in SSA showed a peaking KSHV 
seroprevalence at the age range 33-39 years.[7]  Similarly, our study showed HIV co-
infected males at the age range of 30-37 and females at 26-49 years.  The number of 
females in the cohort was almost double that of the male cohort.  This ratio was also seen 
in the study conducted in the Gauteng and North West Provinces of South Africa.[70]  
The majority of the HIV-positive and HIV-negative participants in our study were Black 
South Africans, and this was representative of the South African population as well as the 
HIV-positive population.[2, 71] 
 
Importantly noted was the significantly higher percentage of participants who were 
unemployed in the HIV-positive group (40%), as compared to the 11% in the HIV-
negative group. This is in keeping with the past research in South Africa, where at least 
one in five HIV-positive individuals were unemployed.[72, 73]   
KZN is the epicenter of the HIV epidemic in South Africa[2, 74], hence choosing an 
urban clinic in central Durban, was appropriate to conduct this cross-sectional study.   
 
4.3 KSHV seroprevalence determined by KSHV ELISA 
This study explored for reactivity to both lytic and latent antigens of KSHV to increase 
the sensitivity and specificity for identifying KSHV-positive participants’.  The total 
cohort seroprevalence was marginally higher (6-20%) compared to Gauteng and North 




When analyzing seropositivity to KSHV as being positive for either lytic or latent 
antibodies, two-thirds of HIV-positive individuals were infected with KSHV, similar to 
West African Ghanaians.[60]  The HIV-positive/KSHV seropositive was higher than the 
Johannesburg cohort and antenatal clinics in Gauteng, 70% vs 48%, 36.1%.[9, 69]  
KSHV seropositivity (37%) of HIV-negative individuals was almost 10 times higher than 
in the USA, Southeast Asia and Caribbean, but correlated with Zambia, Uganda and 
Ghana (37.5%, 38.8% and 41.9% respectively).[53]  Our HIV-negative group was greater 
in KSHV seropositivity than reported in a Ghanaian study (37% vs 23.7%).[60]  
Regarding lytic antibody differences between HIV-positive and HIV-negative 
individuals, 50% of those who were HIV-positive expressed the lytic antibody, which 
was higher than the Johannesburg cohort.[9]   
 
Based on these findings, the HIV-positive individuals had a greater lytic antibody 
expression than those HIV-negative but with no difference between males and females.  
This was in contrast to the Johannesburg cohort, which showed 66% male and 34% 
female lytic antibody levels amongst their HIV-positive participants.  However, the 
Johannesburg cohort consisted only of HIV-positive subjects, making it difficult to draw 
a comparison with an HIV-negative population. 
 
The latent antibody expression in the HIV-positive individuals was 30% higher than the 
Johannesburg cohort [9], with no significant difference between the latent antibody 
expression between the males and females, although the HIV-negative males showed a 
higher latent antigen affinity than the females.  While this study has shown raised 
expressions of lytic and latent antibodies in HIV-positive individuals, there was no 
conclusive differences in reactivity to either antigens between the males and females 
within the HIV-positive and HIV-negative groups. 
 
The study confirms the findings that overall, HIV-positive individuals are more likely to 
be KSHV positive than HIV-negative individuals [9, 20, 60, 66, 69], hence placing them 




4.4 Objective 3:  To evaluate KSHV salivary shedding through cell associated 
KSHV viral loads in those who were KSHV-seropositive  
KSHV DNA was detected in 35% of the cohort from salivary specimens, which suggests 
that KSHV seropositivity does not necessarily imply viral shedding, as seen in another 
local study.[9]  KSHV shedding categories were formulated in order to interpret and 
compare the large variation between the KSHV viral load results.   The positive KSHV 
“shedders” were aged between 29-44 years, which appears to be a common age range for 
HIV/KSHV co-infections.[37, 70] The KSHV viral load on average was higher in HIV-
positive group, however a statistical analysis could not be drawn between the two groups 
as the HIV-negative had fewer detectable viral loads.  The KSHV viral load variance 
between the two groups was significant (p-value < 0.0001).  Similar to this cohort, other 
studies have documented higher KSHV viral loads in HIV-positive individuals, with the 
likely implication for KS pathogenesis, [11, 34, 35] with saliva being a possible route of 
transmission.[35, 42, 47] 
 
There were 24% HIV-positive participants on ART and 14% expressed KSHV 
antibodies, with a low positive KSHV DNA detected in only one participant.  There 
exists a possibility that the ART may have suppressive factors affecting KSHV 
expression and replication, ultimately decreasing KSHV viremia, as shown in other 
studies.[76-80]  Four additional individuals were analyzed from the HIV-negative group 
to detect KSHV DNA, these participants having fallen into the indeterminate category by 
the KSHV ELISA assay.  A low positive KSHV DNA was detected in only one HIV-
negative, indeterminate KSHV participant.      
 
The KSHV viral load quantification in HIV-negative individuals, although lower than in 
the HIV-positive individuals, may warrant further KS screening and monitoring.  The 
significantly higher KSHV viral load in HIV-positive participants not on ART, may 






The study demographics correlated with many similar studies in this field with males and 
females in their mid-twenties to late forties, co-infected with HIV and KSHV.  However, 
contradictory to some studies, the female population was higher and the younger 
individuals were most affected by the co-infection.  The HIV-positive group showed an 
almost four times higher unemployment rate than the HIV-negative group as shown in 
previous studies as well. 
 
Based on this urban South African cohort, just over half the population is positive for 
KSHV.  A third of HIV-negative individuals and two-thirds of HIV-positive individuals 
are KSHV positive based on being positive for either lytic or latent antibodies. It is 
evident that HIV-positive individuals present more frequently with KSHV positivity (p < 
0.0009). 
KSHV DNA was detected in just over a third of those KSHV/HIV-positive with a large 
variance and extremely higher viral burden. KSHV DNA detection was much lower in 
KSHV positive/HIV-negative individuals with a lower variance and lower viral titres. 
The HIV-positive individuals showed a significantly higher viral burden and variance (p-
value < 0.0001) compared to the KSHV positive/HIV-negative.  Historical studies have 
documented higher KSHV viral loads with progression to clinical KS. 
Although participants on ART had lower KSHV viral loads compared to those not on 
ART, using ART as a therapeutic approach to control KSHV infectivity needs further 
investigation.  
The HIV-positive and high viral shedding participants are at high risk of clinical Kaposi’s 
sarcoma and we recommend that they be screened for this malignancy by healthcare 
workers. In addition testing of HIV-positive adults for KSHV is a recommendation so 








CHAPTER 5. CONCLUSION  
 
South Africa is faced with many challenges in addressing the HIV/AIDs epidemic, 
including opportunistic infections, HIV associated malignancies and diseases that hinder 
the quality of patients’ lives. Early identification of those at risk of any of these 
associated conditions is crucial to decreasing this burden.  Kaposi’s sarcoma is the 
commonest malignancy associated with HIV in Sub-Saharan Africa. Despite access to 
treatment the outcome of this condition remains poor. KwaZulu-Natal is the epicenter of 
the HIV epidemic in South Africa and therefore evaluation of the KSHV (the causative 
agent in KS) seroprevalence in this population is vital to decreasing the burden of this 
malignancy.  
 
A high KSHV seroprevalence was demonstrated amongst adults attending an urban HCT 
clinic in KwaZulu-Natal, South Africa. Those co-infected with HIV presented with a 
higher KSHV viral load and are at a higher risk of developing clinical Kaposi’s sarcoma. 
We strongly recommend that all HIV infected patients be screened to prevent the spread 
of this oncogenic virus and those infected be monitored and treated aggressively to 
decrease the burden of KS. 
 
Limitations to the study 
This cross-sectional study only enabled the analysis of samples from one time point.  A 
larger, longitudinal study over a longer time span, with a more extensive specimen and 
data collection would contribute to our understanding of the associations and risks with 
KSHV infection.  Incomplete data on antiretroviral treatment, immune response and 
employment status limited the evaluation of these as risk factors for KSHV viral 









The following recommendations are made as a result of the study findings: 
 Prevention is the key to curbing the spread of KSHV infection and the subsequent 
development of KS. This can be achieved by educating the general population 
and especially the HIV population on KSHV infection and possible modes of 
infection and transmission. Campaigns to promote education on KSHV amongst 
health care workers especially at a primary care level are essential. This can be 
done in forms of information sharing workshops and roadshows. Dissemination 
of pamphlets at clinics, hospitals, schools and tertiary institutes (guest lectures). 
 HIV-positive participants and those with a high KSHV shedding are at high risk of 
clinical Kaposi’s sarcoma, and we recommend that they be screened for this 
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APPENDIX I. PATIENT INFORMATION SHEET (English) 
 
 INFORMATION DOCUMENT 
(Please refer to the UKZN Biomedical Ethics Terms of Reference at 
http://research.ukzn.ac.za/ResearchEthics11415.aspx) 
 
Study title:  SEROPREVALENCE AND VIRAL QUANTIFICATION OF 
KAPOSI’S SARCOMA ASSOCIATED HERPESVIRUS (KSHV) IN A HUMAN 
IMMUNODEFICIENCY VIRUS (HIV) POSITIVE ADULT SOUTH AFRICAN 
COHORT. 
 




In order to take part of this research study, you need to understand the risks and benefits 
so that you can make an informed decision. This is known as informed consent.  Once 
you understand the study, if you agree to participate, you will be asked to sign this form. 
Your decision to take part in the study is voluntary. This means that you are free to 
choose if you will take part in the study and this will not affect any other treatment you 
receive. 
 
The study is being conducted by Dr. Anisa Mosam and Mrs. Shoohana Singh from the 
Department of Dermatology, UKZN. The study is sponsored by CAPRISA. 
 
PURPOSE AND BACKGROUND: 
 
This study is will collect information on a virus called Human Herpes Virus 8 (HHV8) in 
people with and without HIV. In some individuals that have the virus and HIV, it may 
cause a cancer called Kaposi’s Sarcoma. It is hoped that this information will enable us to 
develop appropriate research studies in HHV8 and Kaposi’s Sarcoma.  
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HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
 
70 HIV positive and 70 HIV negative individuals 
 
WHAT WILL HAPPEN IN THE STUDY? 
 
Once you agree to take part in this study, the following will happen: 
Personal information such as age, sex, and ethnicity, medical history, and laboratory 
information including your HIV test results, will be collected on a data sheet.  
You will be required to donate one blood and saliva sample only.  
These samples will be tested to see if you have the HHV8  
 
WHAT ARE THE STUDY RISKS? 
 
You may experience a little discomfort during the blood draw, but the saliva collection is 
totally non-invasive. 
 
WHAT ARE THE BENEFITS OF THE STUDY? 
 
There is no direct medical benefit to you if you agree to take part in this study.  We hope 
that what is learned from this study will help other patients with HIV and HHV8 in the 
future. 
 
WHAT OTHER ALTERNATIVES ARE THERE? 
 
You are free not to take part in the study 
 
PARTICIPATION IS ENTIRELY VOLUNTARY 
 
PARTICIPATION IN RESEARCH IS VOLUNTARY.  
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You are not forced to take part in this study and you are free to withdraw at any stage of 
the study. Refusing to participate will not affect any care that you continue to receive. 
 
WHAT ARE THE COSTS? 
 
There will be no costs to you as a result of taking part in this study. You will be 
reimbursed an amount of R 50.00 (Fifty Rands) for transportation costs. 
 
WHAT ABOUT CONFIDENTIALITY? 
 
Every effort will be made to keep personal information confidential.  Absolute 
confidentiality cannot be guaranteed.  Personal information may be disclosed if required 
by law. 
The Organization that may inspect and/or copy your research records for quality 
assurance and data analysis will be the Biomedical Research Ethics Committee. 
A record of your results for this study will be kept in a confidential form at the CAPRISA 
Clinic located at the Durban Chest Clinic.  The confidentiality of computer records is 




WHOM DO I CALL IF I HAVE QUESTIONS? 
 
For more information regarding the research or research related risks or injuries, please 
feel free to ask the study doctor, Dr. A Mosam 031 360 3550, 031 260 4565 or Ms. 
Shoohana Singh on 031 260 7769 or 084 247 5783.  
 
For questions about your rights as a research participant, contact the Institutional Review 
Board, BIOMEDICAL RESEARCH AND ETHICS ADMINISTRATION (which is a 
group of people who review the research to protect your rights) at 031 2604769, Private 
Bag X 54001 Durban 4000 or email: BREC@ukzn.ac.za 
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APPENDIX II. PATIENT INFORMATION SHEET (isiZulu) 
 
 INCWADI YOLWAZI (INFORMATION DOCUMENT) 
(Please refer to the UKZN Biomedical Ethics Terms of Reference at 
http://research.ukzn.ac.za/ResearchEthics11415.aspx) 
 
Isihloko Socwaningo:  UKWANDA SEKUKONKE KUBANTU ABATHILE 
ESIKHATHINI ESITHILE NJENGOBA KUSUKE KUKALWE 
NGOKUHLOLWA KWEGAZI NOKUBALWA KWESIBALO SAMAGCIWANE 
KWESIFO ESIBIZWA NGE-KAPOSI’ SARCOMA ESIHAMBISANA 
NEGCIWANE LE-HERPES (KSHV) KUBANTU BASENINGIZIMU AFRIKA 
ABELASHWA NDAWONYE NJENGEQEMBU ABANE-HIV NABANGENAYO. 
 
Sawubona futhi sibonga nesikhathi sakho osipha sona. 
 
ISINGENISO: 
Ukuze ukwazi ukubamba iqhaza kulolu cwaningo, kufanele uqonde izingozi nezinzuzo 
ukuze uthathe isinqumo esakhelwe olwazini. Lokhu kwaziwa ngokuthi yimvume 
eyakhelwe olwazini.  Uma usuluqonda ucwaningo, uma uvuma ukubamba iqhaza, 
uzocelwa ukuthi usayine lefomu. Isinqumo sakho sokubamba iqhaza ocwaningweni 
ngokokuzithandela ngokwakho. Lokhu kusho ukuthi ukhululekile ukukhetha ukuthi 
uzolibamba yini iqhaza ocwaningweni kanti lokhu ngeke kube nomthelela kunoma 
yimiphi imithi yokwelashwa oyitholayo. 
 
Ucwaningo lwenziwa uDkt Anisa Mosam noNkk Shoohana Singh abavela emnyangweni 
womkhakha obhekene nokwelashwa kwesikhumba obizwa nge-Department of 
Dermatology e-UKZN. Ucwaningo luxhaswe yi-CAPRISA. 
 
INHLOSO NESENDLALELA: 
Lolu cwaningo luzoqoqa ulwazi ngegciwane elibizwa nge-Human Herpes Virus 8 
(HHV8) kubantu abane-HIV nabangenayo. Kwabanye abantu abanegciwane ne-HIV, 
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lingadala isifo somdlavuza esibizwa nge-Kaposi’s Sarcoma. Kwethenjwa ukuthi lolu 
lwazi luzosivumela ukuthi sisungule ucwaningo nge-HHV8 ne-Kaposi’s Sarcoma.  
 
BANGAKI ABANTU ABAZOBAMBA IQHAZA OCWANINGWENI? 
Abantu abangama-70 abane-HIV nabangama-70 abangenayo. 
 
KUZOKWENZEKANI OCWANINGWENI? 
Uma uvuma ukubamba iqhaza kulolu cwaningo, okulandelayo kuzokwenzeka: 
Ulwazi oluphathelene nawe njengeminyaka yobudala, ubulili, ubuzwe, umlando 
ophathelene nokwelashwa, nolwazi oluphathelene nelabhorethri kubandakanya 
imiphumela yokuhlolelwa i-HIV, luzofakwa ephepheni lemininingwane.  
Uzocelwa ukuthi unikele ngesampula elilodwa kuphela legazi namathe.  
La masampula azohlolwa ukubheka ukuthi ngabe unayo yini i-HHV8.  
 
YIZIPHI IZINGOZI ZOCWANINGO? 
Ungase uzwe ukungaphatheki kahle okuncane ngesikhathi kudonswa igazi, kodwa 
ukuthathwa kwamathe akunayo nencane inkinga. 
 
YIZIPHI IZINZUZO ZOCWANINGO? 
Akukho nzuzo yokwelashwa eqondile kuwe uma uvuma ukubamba iqhaza kulolu 
cwaningo.  Sethemba ukuthi okufundwa kulolu cwaningo kuzosiza iziguli ezine-HIV ne-
HHV8 ngomuso. 
 
YIZIPHI EZINYE IZINDLELA EZIKHONA? 
Ukhululekile ukungabambi iqhaza ocwaningweni 
 
UKUHLANGANYELA KUNGOKOKUZITHANDELA NGOKUPHELELE 
UKUHLANGANYELA OCWANINGWENI KUNGOKOKUZITHANDELA.  
Awuphoqiwe ukubamba iqhaza kulolu cwaningo futhi ukhululekile ukuhoxa kunoma 
yiliphi ibanga locwaningo. Ukwenqaba kwakho ukubamba iqhaza ngeke kube nomthelela 





Ngeke kube khona zindleko eziza kuwena ngenxa yokubamba iqhaza kulolu cwaningo. 




Kuzokwenziwa yonke imizamo ukugcina ulwazi luyimfihlo.  Angeke sikwazi 
ukuqinisekisa imfihlo ephelele.  Ulwazi oluphathelene nawe lungadalulwa uma kudingwa 
umthetho. 
INhlangano engahlola futhi/noma engakopisha amarekhodi akho ocwaningo ukwenzela 
ukuqinisekisa izinga nokuhlaziywa kwemininingwane kuyoba yi-Biomedical Research 
Ethics Committee. 
Irekhodi lemiphumela yakho yalolu cwaningo liyogcinwa efomini eyimfihlo 
emtholampilo wase-CAPRISA osemtholampilo wesifo sesifuba waseThekwini i-Durban 
Chest Clinic.  Ubumfihlo bamarekhodi ekhompyutha bubhekwe ngokuphephile.  Akukho 
lwazi ongaziwa ngalo oluyodedelwa noma lushicilelwe.  
 
NGITHINTA BANI UMA NGINEMIBUZO? 
Olunye ulwazi mayelana nocwaningo noma izingozi noma ukulimala okuphathelene 
nocwaningo, ukhululekile ukuthi ubuze udokotela wocwaningo, Dkt A Mosam ku-031 
360 3550, 031 260 2565 noma uNk Shoohana Singh ku-031 260 7769 noma ku-084 247 
5783.  
 
Ngemibuzo mayelana namalungelo njengombambiqhaza wocwaningo, thintana nebhodi 
lokubuyekeza lesikhungu okuyi-Institutional Review Board, ne-BIOMEDICAL 
RESEARCH AND ETHICS ADMNISTRATION (okuyiqembu labantu ababuyekeza 
ucwaningo ukuvikela amalungelo akho) ku-031 2604769,  Private Bag X 54001 Durban 





APPENDIX III. CONSENT FORM (English) 
CONSENT DOCUMENT 
 
Consent to Participate in Research 
 
SEROPREVALENCE AND VIRAL QUANTIFICATION OF KAPOSI’S 
SARCOMA ASSOCIATED HERPESVIRUS (KSHV) IN A HUMAN 
IMMUNODEFICIENCY VIRUS (HIV) POSITIVE AND NEGATIVE ADULT 
SOUTH AFRICAN COHORT. 
 
I, _________________________________agree to participate in this research study.  
I agree that the study has been explained to me in a language that I can understand and I 
understand the study information sheet. I have discussed the advantages and 
disadvantages of participating in the study. I agree to divulging my HIV status, as well as 
personal and medical information for the purposes of this study only. I also agree to the 
collection of one blood and saliva samples.  
I know that I can leave the research study at any time without prejudice. I will still be 
able to attend and make full use of all the facilities at the clinic as usual. 
 
You may contact Dr. A Mosam 031 360 3550, 031 260 4565 or Shoohana Singh on 031 
260 7769 or 084 247 5783 at any time if you have questions about the research or if you 
are injured as a result of the research. 
 
You may contact the Biomedical Research Ethics Office on 031-260 4769 or 260 1074 or 
Email BREC@ukzn.ac.za if you have questions about your rights as a research 
participant. 
 
Your participation in this research is voluntary, and you will not be penalized or lose 




If you agree to participate, you will be given a signed copy of this document and the 
participant information sheet which is a written summary of the research. 
 
The research study, including the above information, has been described to me orally. I 
understand what my involvement in the study means and I voluntarily agree to 
participate. I have been given an opportunity to ask any questions that I might have about 
participation in the study. 
 
 
____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 














APPENDIX IV. CONSENT FORM (isiZulu)   
INCWADI YEMVUME (CONSENT DOCUMENT) 
 
Imvume yokubamba iqhaza ocwaningweni 
UKWANDA SEKUKONKE KUBANTU ABATHILE ESIKHATHINI ESITHILE 
NJENGOBA KUSUKE KUKALWE NGOKUHLOLWA KWEGAZI 
NOKUBALWA KWESIBALO SAMAGCIWANE KWESIFO ESIBIZWA NGE-
KAPOSI’ SARCOMA ESIHAMBISANA NEGCIWANE LE-HERPES (KSHV) 
KUBANTU BASENINGIZIMU AFRIKA ABELASHWA NDAWONYE 
NJENGEQEMBU ABANE-HIV NABANGENAYO. 
Mina, _________________________________ngiyavuma  ukubamba iqhaza kulolu 
cwaningo.  
Ngiyavuma ukuthi ngiye ngachazelwa ucwaningo ngolimi engiluqondayo futhi 
ngiyaliqonda iphepha lolwazi locwaningo. Ngixoxile ngokuzohlomulisa nokungeke 
okumayelana nokubamba iqhaza ocwaningweni. Ngiyavuma ukudalula isimo sami se-
HIV, kanjalo nolwazi oluphathelene nami nalolo oluphathelene nokwelashwa ukwenzela 
lolu cwaningo kuphela. Ngiyavuma futhi ukuthi kuthathwe isampula elilodwa legazi 
nelamathe.  
Ngiyazi ukuthi ngingashiya noma nini ocwaningweni ngaphandle kokubandlululwa. 
Ngisazokwazi ukuza futhi ngisebenzise ngokugcwele konke okwasemtholampilo 
njengokujwayelekile. 
 
Ungathintana noDkt A Mosam ku-031 360 3550, 031 260 4565 noma no-Shoohana 
Singh ku-031 260 7769 noma ku-084 247 5783 noma nini uma unemibuzo ngocwaningo 
noma ulimala ngenxa yocwaningo. 
Ungathintana ne-Biomedical Research Ethics Office ku-031 260 4769 noma ku-260 1074 





Ukubamba kwakho iqhaza kulolu cwaningo kungukuzithandela ngokwakho, futhi ngeke 
uhlawuliswe noma ungabe usasizakala uma wenqaba ukubamba iqhaza noma uthatha 
isinqumo sokuyeka noma nini. 
Uma uvuma ukuhlanganyela, uzonikezwa ikhophi esayiniwe yale ncwadi kanye 
nephepha lolwazi oluphathelene nombambiqhaza/nomhlanganyeli okuyisifinqo 
esibhaliwe socwaningo. 
 
Isifundo socwaningo, kubandakanya ulwazi olungenhla, ngiye ngachazelwa lona 
ngomlomo. Ngiyakuqonda ukubandakanyeka kwami ocwaningweni ukuthi kusho 
ukuthini futhi ngiyazivumela ngokuthanda kwami ukubamba iqhaza. Ngiye nganikezwa 
ithuba lokubuza noma yimiphi imibuzo engingaba nayo ngokubamba iqhaza 
ocwaningweni. 
 
____________________      ____________________ 
Isignesha yombambiqhaza               Usuku 
 
____________________   _____________________ 
Isignesha kafakazi                           Usuku 
(Lapho kufanele khona)      
 
____________________                   _______________________ 
Isignesha yomhumushi                     Usuku 











APPENDIX V. DATA SHEET 
 
HHV 8 STUDY   DATA SHEET 
 
 DEMOGRAPHICS 
Date:  PID/Study  No:   2806-12- 
Address: 
Phone no: Employment status: 
Race: Age or D.O.B: Gender M F 
 
 IS THE PATIENT CURRENTLY ON ANTI 
RETROVIRAL TREATMENT?    
 
 HAS THE PATIENT EVER BEEN ON 
ANTI-RETROVIRAL TREATMENT?  
IF YES, WHEN WAS IT STARTED AND ENDED AND WHAT WAS THE 
NAMES OF THE MEDICATION? 
 
 INVESTIGATIONS 
PLEASE PROVIDE CD4 AND HIV VIRAL LOAD RESULTS IF THE PATIENT 
HAD THESE TESTS DONE. 
DATE   
CD4 Count   
HIV Viral Load   
 
 









ILLNESS?   
 
IF YES, PLEASE RECORD ON TABLE WHAT THE ILLNESS IS 
HOW LONG (DURATION) THEY EXPERIENCED IT AND IF THEY 
RECEIVED TREATMENT FOR THE ILLNESS 
ILLNESS/ CONDITION   DURATION                
TREATMENT 
   
   
   
   
 IS THERE ANY OTHER IMPORTANT INFORMATION THAT THE 







STAFF COMPLETION: ____________________         DATE:_________________         



































Figure S2:  Standard curve and Amplification curve for K6 – viral gene 
 
 
 
